Rivastigmine For Methamphetamine Dependent Individuals
Substance-Related Disorders

About this trial
This is an interventional treatment trial for Substance-Related Disorders
Eligibility Criteria
Inclusion Criteria: Speaks English Not seeking treatment for methamphetamine dependence at study entry Meets DSM-IV criteria for methamphetamine abuse or dependence Smokes or intravenously uses methamphetamine Resting pulse between 50 and 90 beats per minute within 2 days prior to study entry Systolic blood pressure between 85 and 150 mmHg and diastolic blood pressure between 45 and 90 mmHg within 2 days prior to study entry Electrocardiogram demonstrating normal sinus rhythm, normal conduction, and no clinically significant arrhythmias Medical history and brief physical examination demonstrating no clinically significant contraindications for study participation Exclusion Criteria: History or evidence of seizures or brain injury Previous adverse reaction to methamphetamine Neurological or psychiatric disorders (e.g., psychosis, bipolar illness, or major depression) Organic brain disease or dementia History of any psychiatric disorder that requires ongoing treatment or that would make study compliance difficult History of suicide attempts within the 3 months prior to study entry Heart disease or high blood pressure Family history of early cardiovascular morbidity or mortality Untreated or unstable medical illness, including neuroendocrine, autoimmune, liver, kidney, or active infectious disease HIV infected AIDS-defining illness Currently taking antiretroviral medication Pregnant or breastfeeding Unwilling to use an adequate method of contraception for the duration of the study History of respiratory illness (e.g., asthma, chronic coughing, and wheezing) Currently using alpha or beta agonists, theophylline, or other sympathomimetics
Sites / Locations
- University of California - Los Angeles